PLAU and cancer: In 2016, Yang et al. reported the first immunoPET imaging of uPA in cancer using uPA-targeted antibody ATN-291V conjugated with the positron emitting radionuclide 89Zr (89Zr-Df-ATN-291) in subcutaneous mouse models of five cancer types, including PDAC (BxPC-3), which showed good stability and favourable tumour uptake up to 120 h after tracer administration [242].